Our ACeRT technology (Athergen’s Cell Reprogramming Technology) platform is the synergy of our four groundbreaking technologies that when harnessed together, have the capability to safely reprogram cells in vivo, restoring their epigenetic profile to match the characteristics they displayed in their more youthful state. Our technology enables the modification of chromatin marks, methylation patterns and CpG sites across an entire organism or focus specifically on a particular organ or cell group. Additionally, our platform has the capability to directly convert one cell type into another. Unlike existing and even emerging approaches our innovative technology works at the kernel level to address age-related illnesses and facilitate tissue regeneration by reversing cellular aging. It is versatile and can be applied In-Vitro, In-Vivo and Ex-Vivo.
Our miRNAcle technology is a proprietary novel signaling RNA which radically changes the landscape of in vivo cellular reprogramming by safely reverting the cells epigenetic profile to one that the cell had in its youthful state and engaging inherent ancillary pathways, while simultaneously allowing high controllability and safety in that only the desired result is achieved.
Our novel Tri-Layer Nanovesicle delivery system enables us to navigate our miRNAcle past cellular or organismal barriers. This results in significantly enhanced recruitment and broad-based access, achievable through minimally invasive or non-invasive methods.
Our novel targeting technology allows us to accurately direct our miRNAcle to specific targets, like neurons in the brain for Alzheimer's treatment. Leveraging sophisticated machine learning and generative AI algorithms, we can customize these elements to develop a highly optimized approach, taking into account desired outcomes, target cells, and various epigenetic considerations.
Yamanaka factors, can reprogram adult cells into a pluripotent state similar to embryonic stem cells, allowing them to differentiate into various cell types.
Safety concerns: like integration into the host genome.
Low efficiency: small percentage of treated cells recruited to pluripotency.
Epigenetic memory: of their original cell type, which can influence their differentiation potential and limit their use.
Tumorigenic potential: these factors, particularly c-MYC, can promote the growth and survival of undifferentiated iPSCs.
Targeting: low selectivity, low affinity, or broad systemic influence versus targeted site engagement.
Other challenges: risk of off-target, immunogenicity, etc.
Athergen’s Cell Reprogramming Technology involves the use of specific miRNAs that can partially reprogram cells in vivo by reverting the cell’s epigenetic profile to one that the cell had in its youthful state.
Enhanced safety: non-integrating methods.
Improved efficiency: targets single or multiple sites and cell types, modulates post-transcriptional gene expression, more reliable.
Modulation of epigenetic memory: effectively erases the epigenetic memory of somatic cells, directly altering the chromatin marks, methylation pattern.
Increased safety: employs non-oncogenic miRNAs and activates natural in vivo protective pathways like p53 and Sirtuins.
Direct reprogramming potential: miRNAs can quickly convert one cell type to another, bypassing pluripotent stages.
Other benefits include Simplicity and Versatility and can be used in-Vivo, in-Vitro, or ex-Vivo.